On July 7th, the National Medical Insurance Administration announced the preliminary form review results of the 2024 National Medical Insurance Drug Catalog. From 9:00 am on July 1st to 5:00 pm on July 14th, 2024, a total of 626 enterprise application information were received, involving 574 drugs. After review, 440 drugs have passed the preliminary formal examination. Compared to 2023, the number of declared drugs has increased. The adjustment of the medical insurance drug catalog is divided into several stages, including enterprise application, formal review, expert evaluation, negotiation and bidding. Among them, formal examination is the review of whether the declared drugs meet the conditions for adjusting the national medical insurance drug catalog and the completeness of drug information in the current year. It mainly consists of four steps: initial examination, public announcement of initial examination results, re examination, and announcement of re examination results. The National Healthcare Security Administration introduced that the content of this public announcement is the preliminary review results of this year. A drug that has passed the preliminary formal examination only represents that it meets the application requirements and is eligible to participate in the catalog adjustment, and does not mean that it has entered the national medical insurance drug catalog. The deadline for this public announcement is August 13th. Based on the feedback received during the announcement period, the National Healthcare Security Administration will further verify the relevant information, determine the final list of drugs that have passed the formal review, publish it to the public, and promote subsequent work such as expert review and negotiation bidding. (New Society)